Development of a biomarker of fibromyalgia on neuroinflammation. - Development of a biomarker of fibromyalgia on neuroinflammation.

Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University0 个研究点目标入组 80 人开始时间: 2022年9月12日最近更新: 2024年5月27日

试验速览

暂无简介。

•[Fibromyalgia] (1) Patients with symptoms of anemia (hemoglobin 8 g/dl or less) (2) Patients with poor general condition (PS value >3) (3) Patients diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), malignant disease (4) Other patients deemed by the investigator to be inappropriate as research subjects. [Chronic pain] (1) Patients with symptoms of anemia (hemoglobin of 8 g/dl or less) (2) Patients with poor general condition (numerical value: PS value 3 or higher) (3) Those diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), or malignant disease (4) Other subjects deemed by the investigator to be inappropriate as research subjects. [Healthy control] (1) Those with symptoms of anemia (hemoglobin 8 g/dl or less) (2) Patients with poor general condition (PS value of 3 or higher) (3) Patients receiving treatment for pain (4) Those diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), or malignant disease (5) Any other person whom the investigator deems inappropriate as a research subject.

发起方

Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University